2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.
Jane L. Meisel, MD, associate professor, the Department of Hematology and Medical Oncology, Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses the effect of the HER2-low classification for patients with breast cancer.
Meisel estimates that approximately two-thirds of patients with metastatic estrogen receptor (ER)–positive breast cancer could be considered HER2-low, and these patients previously would have been deemed HER2-negative. Although it is likely a smaller proportion of patients with hormone receptor–negative disease is HER2-low, a substantial number of patients with metastatic breast cancer could fall under the new HER2-low classification, Meisel adds.
Improved standardization for the assessment of HER2 status will be important for patients with metastatic breast cancer, particularly as more HER2-targeted agents are developed in clinical trials and evaluated in different patient populations, Meisel concludes.
Related Content: